Describe The Mechanism of Action of Guselkumab

Join Danielle Gatti Palumbo, PharmD, a clinical pharmacist at Northwell Health’s Division of Rheumatology in Long Island, New York, as she provides an in-depth analysis of Guselkumab, a monoclonal antibody that targets IL-23 to treat immune-mediated inflammatory diseases. This session is essential for rheumatology and gastroenterology APPs, pharmacists, and healthcare providers looking to enhance their understanding of targeted immunotherapy for conditions such as psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

In this video, Danielle explores the role of IL-23 in driving chronic inflammation and autoimmune disease, explaining how TH17 activation contributes to the pathogenesis of psoriasis, psoriatic arthritis, and inflammatory bowel disease. She examines the impact of IL-17A, IL-17F, and IL-22 in skin, joint, and gut inflammation and highlights Guselkumab’s dual-binding mechanism. By targeting both IL-23 and CD64-expressing cells, Guselkumab enhances efficacy while minimizing off-target effects, leading to improved disease outcomes for patients.

For healthcare professionals involved in the management of immune-mediated diseases, understanding IL-23 inhibition is key to optimizing treatment strategies.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.